Journal issues > Issue 6, October 2018 > Prognostic and predictive value of primary tumour location in metastatic colorectal cancer: will the side change our treatment?

Prognostic and predictive value of primary tumour location in metastatic colorectal cancer: will the side change our treatment?

By: V. de Weerdt MD, E. van Cutsem MD, PhD

Metastatic colorectal cancer is a heterogeneous disease. Tumours arising from different regions of the colon are clinically and molecularly distinct. The differing molecular characteristics translate into a differential clinical outcome with right-sided tumours displaying a worse prognosis compared to left-sided tumours. Besides the prognostic relevance of the primary tumour location, several retrospective analyses suggest that the primary tumour location may also be predictive of treatment benefit from targeted therapy with anti-EGFR and anti-VEGF directed agents in the first-line treatment of RAS wild-type metastatic colorectal cancer.

(BELG J MED ONCOL 2018;12(6):271–274)

To read the full artice you have the following options:

* (only possible for healthcare professionals with RIZIV/INAMI/MATRICULE working in the field of Oncology/Hemato-oncology in Belgium and Luxembourg with prescription authorisation)

Purchase this article for €3.03

** (for healthcare professionals with prescribing authorisation working outside the field of Oncology/Hemato-oncology in Belgium and Luxembourg as well as those without prescribing authorisation working as healthcare professional in Oncology/Hemato-oncology in Belgium and Luxembourg, plus persons without prescription authorisation working outside Belgium and Luxembourg, plus healthcare professionals with prescribing authorisation outside Belgium and Luxembourg plus non-healthcare professionals from outside or inside Belgium or Luxembourg)

Top